BACKGROUND: The noninferiority of a 6-week dosing schedule of lanreotide Autogel (Lan ATG) at a dose of 120 mg compared with a 3-week dosing schedule of lanreotide microparticles (Lan MP) at a dose of 60 mg was investigated in patients with neuroendocrine tumors (NET). METHODS:Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial. Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks). Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18. Success was classified as a response that ranged from disappearance to an increase <25% in tumor marker, tumor size, or symptom frequency. RESULTS:Sixty patients were randomized, and 46 patients completed the study. Both for tumor markers and for tumor size, Lan ATG was not inferior to Lan MP (55% and 59% of patients responded on tumor markers, respectively; 68% and 66% of patients responded on tumor size, respectively). There were too few symptomatic patients to compare carcinoid symptoms. Both treatments were tolerated well, and no safety concerns were identified. CONCLUSIONS: Lan ATG at a dose of 120 mg every 6 weeks was as effective for controlling NET as Lan MP at a dose of 60 mg every 3 weeks.
RCT Entities:
BACKGROUND: The noninferiority of a 6-week dosing schedule of lanreotide Autogel (Lan ATG) at a dose of 120 mg compared with a 3-week dosing schedule of lanreotide microparticles (Lan MP) at a dose of 60 mg was investigated in patients with neuroendocrine tumors (NET). METHODS:Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial. Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks). Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18. Success was classified as a response that ranged from disappearance to an increase <25% in tumor marker, tumor size, or symptom frequency. RESULTS: Sixty patients were randomized, and 46 patients completed the study. Both for tumor markers and for tumor size, Lan ATG was not inferior to Lan MP (55% and 59% of patients responded on tumor markers, respectively; 68% and 66% of patients responded on tumor size, respectively). There were too few symptomatic patients to compare carcinoid symptoms. Both treatments were tolerated well, and no safety concerns were identified. CONCLUSIONS:Lan ATG at a dose of 120 mg every 6 weeks was as effective for controlling NET as Lan MP at a dose of 60 mg every 3 weeks.
Authors: A Bianchi; L De Marinis; A Fusco; F Lugli; L Tartaglione; D Milardi; M Mormando; A P Lassandro; R Paragliola; C A Rota; S Della Casa; S M Corsello; M G Brizi; A Pontecorvi Journal: J Endocrinol Invest Date: 2011-11-07 Impact factor: 4.256
Authors: P Ferolla; A Faggiano; F Grimaldi; D Ferone; G Scarpelli; V Ramundo; R Severino; M C Bellucci; L M Camera; G Lombardi; G Angeletti; A Colao Journal: J Endocrinol Invest Date: 2011-07-13 Impact factor: 4.256
Authors: Adrian Lee; David L Chan; Matthew H Wong; Bob T Li; Sumit Lumba; Stephen J Clarke; Jaswinder Samra; Nick Pavlakis Journal: Neuroendocrinology Date: 2016-04-16 Impact factor: 4.914
Authors: George A Fisher; Edward M Wolin; Nilani Liyanage; Susan Pitman Lowenthal; Beloo Mirakhur; Rodney F Pommier; Montaser Shaheen; Aaron Vinik Journal: Oncologist Date: 2017-10-16
Authors: Anne Klibanski; Shlomo Melmed; David R Clemmons; Annamaria Colao; Regina S Cunningham; Mark E Molitch; Aaron I Vinik; Daphne T Adelman; Karen J P Liebert Journal: Pituitary Date: 2010-09 Impact factor: 4.107